Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Skin Cancer: Independent Conference Coverage of the 2021 ASCO Scientific Meeting
  • CME

Michael A. Davies, MD, PhD
Evan J. Lipson, MD
Released: August 4, 2021
Back Next

References

  1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067:6.5-year outcomes in patients (pts) with advanced melanoma. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 9506.
  2. Balch CM, Gershenwald JE, Soong S-j, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206
  3. Glitza IC, Davies MA. Genotyping of cutaneous melanoma. Chin Clin Oncol. 2014;3:27.
  4. Simeone E, Ascierto PA. Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Manag. 2017;4:175-178.
  5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
  6. Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicenter randomized phase 2 study. Lancet Oncol. 2018;19:672-681.
  7. Long GV, Atkinson V, Lo S, et al. Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 9508.
  8. Tawbi HA, Forsyth PA, Hodi FS, et al. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-Oncology. 2021;[Epub ahead of print].
  9. Kluger HM, Chiang V, Mahajan A, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol. 2019;37:52-60.
  10. Foppen MHG, Boogerd W, Blank CU, et al. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. Melanoma Res. 2018;28:126-133.
  11. Lebbe C, Meyer N, Mortier L, et al. Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: 3-year results of CheckMate 511. Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 9516.
  12. Tarhini A, Lin Y, Lin H, et al. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018;6:112.
  13. ClinicalTrials.gov. A phase II study of open label low dose ipilimumab in combination with pembrolizumab in metastatic melanoma patients with brain metastases. clinicaltrials.gov/ct2/show/NCT03873818. Accessed July 27, 2021.
  14. Lipson EJ, Tawbi HA, Schadendorf D, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047). Presented at: 2021 American Society of Clinical Oncology Virtual Annual Meeting; June 4-8, 2021. Abstract 9503.
  15. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012 Feb 15;72;917-927.
  16. Ascierto PA, Melero I, Bhatia S, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. Presented at: 2017 American Society of Clinical Oncology Annual Meeting; June 2-6, 2017. Abstract 9520.
  17. Lipson E, Gopal A, Neelapu SS, et al. Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies. Presented at: 31st Annual Meeting of the Society for Immunotherapy of Cancer; November 9-13, 2016. Abstract P232
  18. Okazaki T, Ozazaki I-M, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208;395.
  19. Amaria RN, Postow MA, Tetzlaff MT, et al. Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG-3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9502.
  20. Amaria RN, Menzies AM, Rozeman EA, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019;20:e378.
  21. Topalian, SL, Bhatia, S, Amin, A., et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020;38:2476-2487.
  22. Dummer R, Flaherty K, Robert C, et al. Five-year overall survival (OS) in COLUMBUS: a randomized phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients (pts) with BRAFV600-mutant melanoma. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9507.
  23. Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38:3947.
  24. Encorafenib [prescribing information]. Boulder, CO: Array; 2020.
  25. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019 Aug 15;381:626-636.
  26. Ascierto PA, Dreno B, Larkin J, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAF v600 mutation-positive advanced melanoma: extended follow-up of the coBRIM Study. Clin Cancer Res. 2021;Jun 22:clincanres.0809.2021.
  27. Eberlein B, Biedermann T, Hein R, Posch C. Vemurafenib-related photosensitivity. J Dtsch Dermatol Ges. 2020;18:1079-1083.
  28. Grogan N, Swami U, Bossler AD, et al. Toxicities with targeted therapies after immunotherapy in metastatic melanoma. Melanoma Res. 2018;28:600-604.
  29. Larkin JMG, Sarnaik A, Chesney JA, et al. Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: evaluation of impact of prior anti-PD-1 therapy. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9505.
  30. Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012;14:468-474.
  31. Arance AM, Cruz-Merino L, Petrella TM, et al. Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9504.
  32. Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019 Feb 27;14:e0212513.
  33. Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109:3993-4002.
  34. Adachi Y, Kamiyama H, Ichikawa K, et al. Inhibition of FGFR signaling by lenvatinib activates tumor interferon gamma signaling pathway and potentiates antitumor activity of anti-PD-1 antibody. Presented at: 2020 AACR Annual Meeting; April 27-28, 2020 and June 22-24, 2020. Abstract 6637.
  35. Eggermont AM, Blank C, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789-1801.
  36. Eggermont AM, Meshcheryakov A, Atkinson V, et al. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab vs placebo after complete resection of high-risk stage III melanoma. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9500.
  37. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings